Source comparison
BPC-157 ARA-290 for Neuropathy Research: Study Design Comparison
BPC-157 VEGF upregulation, angiogenesis, endothelial repair Sciatic nerve crush models (rats). Functional recovery at 10 μg/kg IP No completed human neuropathy trials Subcutaneous, intramuscular, oral (animal data only) Unknown in humans; dosing extrapolated f
This comparison does not assign a generated winner or score.
- BPC-157
- VEGF upregulation, angiogenesis, endothelial repair
- Sciatic nerve crush models (rats). Functional recovery at 10 μg/kg IP
- No completed human neuropathy trials
- Subcutaneous, intramuscular, oral (animal data only)
- Unknown in humans; dosing extrapolated from rodent mg/kg scaling
- Mechanism plausible for ischemic/diabetic neuropathy; lacks Phase 1 safety data in humans
- ARA-290
- Innate repair receptor (CD131/EPOR) activation, anti-inflammatory, anti-apoptotic
- CIPN prevention (mouse models), small fiber repair in sarcoidosis
- Phase 2 completed in sarcoidosis neuropathy (n=28, 2015)
- Subcutaneous injection
- Approximately 8–10 hours; dosed 3× weekly in trials
- Demonstrated measurable nerve fiber density improvement in small human trial; lacks large-scale replication
- Combination Use
- Theoretical synergy (vascular + immune modulation)
- No published studies combining both peptides
- Not investigated
- N/A
- No evidence base for combined efficacy; individual mechanisms suggest non-overlapping pathways